The foreseen modest growth in the overall anti-hypertensive market is clearly satiable due to the lack of hypertension awareness and/or innovative products in late-stage clinical development, followed by low diagnosis and treatment rates combined with weaker pipeline and lack of first-in-class products. No major impact is expected in the global anti-hypertensive therapeutics market for at least the next 6 years. However, one of the markets’ to see an impressive growth is India; which is expecting double digit growth, to create a platform for companies to re-focus their market strategies.
GBI Research’s Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 report covers key APAC markets namely – Australia, China, India, and Japan, including annualised market data from 2014 with forecasts to 2021.
The report will enable you to:
- Understand the clinical context of hypertension by considering symptoms, etiology, pathophysiology, co-morbidities and complications, epidemiology, diagnosis, and treatment options
- Identify therapeutic strategies, new products, and companies that dominate the current marketed products landscape
- Recognise key anti-hypertensive pipeline trends in molecule type, administration route, mechanism of action and novelty
- Review market opportunities and potential risks by examining trends clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action
- Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, and Japan
- Discover trends in licensing and co-development deals concerning anti-hypertensive products and identify the major strategic consolidations that have shaped the commercial landscape
India’s anti-hypertensive therapeutics will expand at the fastest CAGR, find out more!